SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

Investors are actively debating the viability of the TRUMP crypto token, with significant community division between those calling it a failed scam that has lost nearly all its value and those holding out for a potential short squeeze or political-driven rebound. Much of the discourse focuses on the token's massive decline from its peak, leading to heated accusations of financial manipulation and fraud directed at the Trump brand and its associates.

Anthropic

Anthropic is trending due to heightened regulatory scrutiny over its advanced AI models, including government-ordered usage halts, alongside significant investor interest surrounding its anticipated IPO. The community is actively debating the company's complex partnerships with major tech infrastructure providers, its competition with OpenAI, and the potential impact of forthcoming AI governance frameworks on its growth trajectory.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as investors debate the impact of potential future catalysts like tokenization initiatives and legislative clarity, set against a backdrop of intense community disagreement between those calling for a turnaround and others labeling the project a failing asset. The discourse is marked by highly polarized sentiment, with some participants aggressively highlighting technical support levels while others dismiss the price action as a cycle of perpetual dilution and speculative traps.

Investment Managers Series Trust II - Tradr 2X Long ASTS Daily ETF

Tradr 2X Long ASTS Daily ETF

The Tradr 2X Long ASTS Daily ETF ($ASTX) is experiencing intense community focus as traders debate the risks and rewards of leveraging the high volatility of the underlying satellite stock. Investors are actively discussing the impact of daily decay and extreme price swings, with many using the ETF to capitalize on rapid momentum shifts while others warn of the dangers of holding such leveraged products during market corrections.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending due to the company's recent filing for a new SpaceX-focused option income strategy ETF, combined with intense community focus on the fund's shifting portfolio strategy and the impact of its recent reverse stock split. Investors are actively debating the sustainability of current yield payouts versus long-term NAV erosion, with some users employing mechanical 'inverted pairing' systems to mitigate volatility while others express frustration over dwindling dividend distributions.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is generating significant buzz as traders navigate intense price volatility and persistent accusations of algorithmic manipulation. The community remains largely bullish, focusing on the company's strong ad-tech fundamentals and the anticipation of growth catalysts, even as the stock struggles against broader software sector headwinds.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is seeing heightened activity as the community debates its utility, RWA tokenization potential, and recent integrations with major financial infrastructure providers like the DTCC. While some investors express frustration over price performance and stagnant volume, others are actively accumulating tokens, citing strong long-term fundamentals and the potential for a massive decoupling from broader market volatility.

TOSHI

TOSHI is trending as the community expresses strong conviction in its pivot toward AI utility and revenue-sharing mechanisms, viewing current price levels as a prime accumulation zone. Investors are actively discussing the potential for a major breakout, citing the project's massive holder base and upcoming ecosystem developments as catalysts for a long-term recovery.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech shares are experiencing increased volatility as investors weigh the company's ambitious oncology pipeline transition against leadership departures and broader regulatory scrutiny facing the mRNA sector. While the community remains divided over the firm's long-term valuation and clinical execution, discussions are heavily focused on upcoming Phase 3 data readouts that will determine the company's ability to diversify beyond its COVID-19 revenue base.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is attracting intense debate as the community remains divided between those viewing the current price action as a generational buying opportunity and critics who point to concerns over governance and market performance. Investors are actively watching technical support levels while speculating on potential catalysts like protocol upgrades and regulatory developments to drive a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty

Amphastar Pharmaceuticals, Inc. (AMPH) Price Target Cut to $21 At Piper Sandler Amid Pipeline Uncertainty...

Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of -40.28% and +0.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates

Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) have been given a consensus rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and tw...

AMPH vs. RDY: Which Stock Should Value Investors Buy Now?

AMPH vs. RDY: Which Stock Is the Better Value Option?

Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Amphastar Pharmaceuticals (AMPH) to Release Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-amphastar-pharmaceuticals-inc-stock...

Boston Trust Walden Corp Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Boston Trust Walden Corp lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,087,266 shares...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

AMPHAmphastar Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AMPH News